All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study

Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity in patients with hepatitis C virus (HCV) genotype 1b (GT‐1b) infection in the HALLMARK DUAL trial. This post hoc analysis was conducted to determine the efficacy and safety of this treatment in Asian patients.

[1]  J. Kao.  Hepatitis C virus infection in Taiwan: Past, present, and future. , 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.

[2]  Y. Karino,et al.  High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms , 2015, Advances in Therapy.

[3]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[4]  M. Manns,et al.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study , 2014, The Lancet.

[5]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[6]  Chien-Jen Chen,et al.  Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma , 2014, International journal of cancer.

[7]  S. Ahn,et al.  Emerging Therapies for Hepatitis C , 2014, Gut and liver.

[8]  G. Ippolito,et al.  Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach. , 2014, The new microbiologica.

[9]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[10]  H. Lee,et al.  Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study , 2013, Journal of medical virology.

[11]  R. Chien,et al.  Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C , 2013, Alimentary pharmacology & therapeutics.

[12]  E. Cho,et al.  Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience , 2012, Clinical and molecular hepatology.

[13]  G. Foster,et al.  Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection , 2012, Therapeutic advances in gastroenterology.

[14]  K. Chayama,et al.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.

[15]  M. Bourlière,et al.  Future treatment of patients with HCV cirrhosis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[16]  Anna Persson,et al.  Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.

[17]  W. Tak,et al.  Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis , 2011, The Korean journal of hepatology.

[18]  F. Poordad,et al.  Virological relapse in chronic hepatitis C , 2008, Antiviral therapy.

[19]  Ding‐Shinn Chen,et al.  Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Han,et al.  [Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C]. , 2008, The Korean journal of hepatology.

[21]  M. Choi,et al.  [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea]. , 2006, The Korean journal of hepatology.

[22]  M. Kugelmas,et al.  Management of hepatitis C: evaluating suitability for drug therapy. , 2004, American family physician.